Literature DB >> 25840792

CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells.

Asim Pervaiz1, Shariq Ansari, Martin R Berger, Hassan Adwan.   

Abstract

Alterations in the expression of C-C chemokine receptor type 5 (CCR5 or CD195) have been correlated with disease progression in different cancers. Recently, a few investigations have reported the blockage of this receptor by an antagonist (maraviroc) and its antineoplastic effects on tumor cell growth. However, little is known about the mechanistic reasons behind these antineoplastic effects of CCR5 blockage by maraviroc. In this study, we blocked the CCR5 receptor by maraviroc in SW480 and SW620 colorectal cancer cells to study the resulting changes in biological properties and related pathways. This blockage induced significantly reduced proliferation and a profound arrest in G1 phase of the cell cycle. Concomitantly, maraviroc caused significant signs of apoptosis at morphological level. Significant modulation of multiple apoptosis-relevant genes was also noticed at mRNA levels. In addition, we found remarkable increases in cleaved caspases at protein level. These modulations led us to propose a signaling pathway for the observed apoptotic effects. In conclusion, blocking the CCR5 by maraviroc induces significant cytotoxic and apoptotic effects in colorectal cancer cells. Thus, maraviroc can be considered a model compound, which may foster the development of further CCR5 antagonists to be used for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25840792     DOI: 10.1007/s12032-015-0607-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

Review 3.  Apoptosis signaling pathways and lymphocyte homeostasis.

Authors:  Guangwu Xu; Yufang Shi
Journal:  Cell Res       Date:  2007-09       Impact factor: 25.617

4.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1.

Authors:  L Gu; S Tseng; R M Horner; C Tam; M Loda; B J Rollins
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  CCR5 antagonist blocks metastasis of basal breast cancer cells.

Authors:  Marco Velasco-Velázquez; Xuanmao Jiao; Marisol De La Fuente; Timothy G Pestell; Adam Ertel; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2012-05-25       Impact factor: 12.701

6.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.

Authors:  Marco Erreni; Alberto Mantovani; Paola Allavena
Journal:  Cancer Microenviron       Date:  2010-09-17

Review 7.  Chemokine: receptor structure, interactions, and antagonism.

Authors:  Samantha J Allen; Susan E Crown; Tracy M Handel
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 8.  Chemokine receptor CCR5: insights into structure, function, and regulation.

Authors:  Martin Oppermann
Journal:  Cell Signal       Date:  2004-11       Impact factor: 4.315

Review 9.  Current status of screening for colorectal cancer.

Authors:  K Garborg; Ø Holme; M Løberg; M Kalager; H O Adami; M Bretthauer
Journal:  Ann Oncol       Date:  2013-04-25       Impact factor: 32.976

Review 10.  Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.

Authors:  Raymond Yost; Timothy R Pasquale; Eric G Sahloff
Journal:  Am J Health Syst Pharm       Date:  2009-04-15       Impact factor: 2.637

View more
  15 in total

Review 1.  Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Authors:  Xuanmao Jiao; Omar Nawab; Tejal Patel; Andrew V Kossenkov; Niels Halama; Dirk Jaeger; Richard G Pestell
Journal:  Cancer Res       Date:  2019-07-10       Impact factor: 12.701

2.  Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report.

Authors:  Shariq S Ansari; Nurullah Akgün; Martin R Berger
Journal:  Cell Oncol (Dordr)       Date:  2016-11-03       Impact factor: 6.730

3.  Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells.

Authors:  Jie Zi; Shushu Yuan; Jianlin Qiao; Kai Zhao; Linyan Xu; Kunming Qi; Kailin Xu; Lingyu Zeng
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

4.  Expression profiling of anticancer genes in colorectal cancer patients and their in vitro induction by riproximin, a ribosomal inactivating plant protein.

Authors:  Asim Pervaiz; Talha Saleem; Kinzah Kanwal; Syed Mohsin Raza; Sana Iqbal; Michael Zepp; Rania B Georges; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-17       Impact factor: 4.322

Review 5.  The G protein coupled receptor CCR5 in cancer.

Authors:  Chandan Upadhyaya; Xuanmao Jiao; Anthony Ashton; Kishan Patel; Andrew V Kossenkov; Richard G Pestell
Journal:  Adv Cancer Res       Date:  2020-01-10       Impact factor: 6.242

6.  Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening.

Authors:  Mariam A El-Zohairy; Darius P Zlotos; Martin R Berger; Hassan H Adwan; Yasmine M Mandour
Journal:  ACS Omega       Date:  2021-04-16

Review 7.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

8.  Blocking the CCL5-CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells.

Authors:  Yuan Zhuang; Xiaomei Zhao; Baoying Yuan; Zhaochong Zeng; Yixing Chen
Journal:  J Hepatocell Carcinoma       Date:  2021-06-18

9.  CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.

Authors:  Asim Pervaiz; Michael Zepp; Saqib Mahmood; Doaa Mohamed Ali; Martin R Berger; Hassan Adwan
Journal:  Cell Oncol (Dordr)       Date:  2018-11-19       Impact factor: 7.051

10.  IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis.

Authors:  Michael Zepp; Marineta Kovacheva; Munkhtsetseg Altankhuyag; Gabriela Westphal; Irina Berger; Katharina S Gather; Heidegard Hilbig; Jochen Neuhaus; Gertrud M Hänsch; Franz P Armbruster; Martin R Berger
Journal:  J Pathol Clin Res       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.